

Glenmark faces patent suit in US for cancer drug

New Delhi: Glenmark Pharmaceuticals has been slapped with a patent infringement case by US-based Cephalon over plans to sell generic version of leukaemia treatment drug Treanda in the American market.

"Glenmark Pharmaceuticals and Glenmark Generics, USA (Glenmark) confirms Cephalon has filed a

patent infringement suit on December 26, 2013, in the US District Court for the district of Delaware seeking to prevent Glenmark from commercializing its abbreviated new drug application (ANDA) for Bendamustine Hydrochloride product," the company said.

The complaint has been filed against Glenmark try-

ing to commercialize the product before the expiry of patent which is a generic version of Treanda, it added. "A complaint against Glenmark has been filed on US patent 8,445,524," Glenmark said.

Bendamustine is indicated for the treatment of patients with chronic lymphocytic leukemia, it added. AGENCIES

Regulatory Company.